You are here

Pfizer Opens a Call for Proposals for LabCentral Residency

An Opportunity for Neuroscience-Related Startups to be Awarded a Golden Ticket*

Pfizer has opened the call for interested U.S. startup companies focused on neuroscience to submit non-confidential proposals for a Pfizer-sponsored LabCentral Golden Ticket.

LabCentral is a first-of-its-kind shared laboratory space located in the heart of Cambridge, MA, proximate to Pfizer’s campus in Kendall Square, and designed as a launchpad for high-potential life sciences and biotech startups. As a LabCentral platinum sponsor, Pfizer can select up to two startup companies each year to take up residence in LabCentral’s Kendall Square facility. The Golden Ticket will provide a selected startup with one year of bench space for one scientist, including the benefits of shared infrastructure and services.

By providing these LabCentral residencies, Pfizer is focused on supporting the entrepreneurial, early stage activities of true startup companies working in the neuroscience field, which are critical in an area of science that is still nascent. High-potential eligible applicants working in the areas of neuro-degeneration, neuro-inflammation, and neuro-metabolic as well as those developing technology platforms that could ultimately be used to advance neuroscience programs, will be considered.

Interested companies meeting the program eligibility requirements can submit an application for consideration by July 20, 2018.

 

* No purchase or payment of money is necessary to apply or win. At Pfizer’s discretion, up to two Golden Tickets for waitlist priority and a voucher for one year of prepaid rent for a reserved bench for one scientist at LabCentral (est. value $54,180) may be awarded. Use of Golden Ticket subject to conditions including space availability, approval of LabCentral, and a separate agreement with LabCentral. Pfizer is not obligated to award any Golden Tickets. Submit a non-confidential application between 6/7/18 (2:00 pm EDT) and 7/20/18 (11:59 pm EDT). Open only to U.S. startup companies (excluding Arizona) working in the field or related field of neuroscience and/or neuroscience technology platforms who have raised less than $7.5 million in cumulative capital funding and do not have more than $3 million in trailing 12-month revenue. Other eligibility restrictions apply. Limit one application per entity. This is only a summary of the complete terms and conditions. For official terms, including judging criteria and how to apply, visit www.pfizer.com/GoldenTicket. Void where prohibited. Program conducted by Pfizer Inc., 1 Portland St., Cambridge, MA 02139.